Arterial structure and function in patients with acute coronary syndrome after 1year treatment

Insights

One year of pharmacological therapy after non-ST-elevation myocardial infarction (NSTEMI) significantly reduced intima-media thickness (IMT) but did not alter arterial stiffness. This finding is crucial for managing atherosclerosis progression in NSTEMI survivors.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Pharmacology
  • Vascular Biology

Background:

  • The impact of pharmacological therapy on arterial stiffness and intima-media thickness (IMT) in patients with significant atherosclerosis remains debated.
  • Non-ST-elevation myocardial infarction (NSTEMI) survivors present a critical group for evaluating interventions targeting vascular health.

Purpose of the Study:

  • To assess the 1-year effects of guideline-adherent pharmacological therapy on arterial stiffness and IMT in NSTEMI survivors.
  • To investigate whether baseline or follow-up systolic blood pressure influences these vascular changes.

Main Methods:

  • A cohort of 298 NSTEMI patients received standard pharmacological treatment for 12 months.
  • Noninvasive measurements of local (carotid) arterial stiffness and IMT were performed at baseline and after 1 year.
  • Patients were stratified based on systolic blood pressure (<140 mm Hg vs. ≥140 mm Hg) at the 12-month follow-up.

Main Results:

  • No significant changes in arterial stiffness were observed between normal and elevated systolic blood pressure groups at 12 months (P = 0.67 and P = 0.05).
  • A significant reduction in intima-media thickness (IMT) was found in both systolic blood pressure groups (P = 0.0003 and P = 0.001).
  • Age and mean blood pressure influenced arterial stiffness and IMT, but multivariate analysis confirmed these results were independent of these factors.

Conclusions:

  • One-year pharmacological treatment following NSTEMI effectively reduces intima-media thickness (IMT).
  • The studied pharmacological regimen did not significantly alter arterial stiffness properties in NSTEMI survivors.
  • Further research may be needed to identify therapies that can modify arterial stiffness in this patient population.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
353
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
358
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
590
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
427